The critical role of the pathologist in determining eligibility for active survlnc. as a mgmt. option in patients with prostate cancer: Consensus statement with recommendations supported by the Coll. of Amer. Pathologists, Intl. Soc. of Urological Pathol., Assoc. of Directors of Anat. and Surg. Pathol., the New Zealand Soc. of Pathologists, and the Prostate Cancer Found.

Mahul B. Amin, Daniel W. Lin, John L. Gore, John R. Srigley, Hema Samaratunga, Lars Egevad, Mark Rubin, John Nacey, H. Ballentine Carter, Laurence Klotz, Howard Sandler, Anthony L. Zietman, Stuart Holden, Rodolfo Montironi, Peter A. Humphrey, Andrew J. Evans, Jonathan I. Epstein, Brett Delahunt, Jesse K. McKenney, Dan BerneyThomas M. Wheeler, Arul M. Chinnaiyan, Lawrence True, Beatrice Knudsen, M. Elizabeth H. Hammond

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'The critical role of the pathologist in determining eligibility for active survlnc. as a mgmt. option in patients with prostate cancer: Consensus statement with recommendations supported by the Coll. of Amer. Pathologists, Intl. Soc. of Urological Pathol., Assoc. of Directors of Anat. and Surg. Pathol., the New Zealand Soc. of Pathologists, and the Prostate Cancer Found.'. Together they form a unique fingerprint.

Medicine & Life Sciences